GSK plc

Precision Neuroscience Names Verily Co-Founder Brian Otis as Chief Technology Officer

Retrieved on: 
Monday, April 8, 2024
Speech, GSK plc, Dexcom, ALS, Paralysis, Diabetes, Patient, Conditional sentence, Instrument, Heel, Electronics, Research, Otis, News, University, Computer engineering, Electricity, G7, Precision, FDA, Movement, Medical device

NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.

Key Points: 
  • NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision) today announced that Dr. Brian Otis has joined the company as Chief Technology Officer.
  • He was one of the co-founders of Verily, Alphabet Inc.’s healthcare and life sciences company, where he served as Chief Technical Officer and Fellow from 2015 through 2022.
  • He oversaw a large, multidisciplinary team in the end-to-end development of new medical technology, from discovery to manufacturing.
  • Under Otis’ technical leadership, Verily entered a number of significant collaborations with leading healthcare and pharmaceutical partners.

Autolus Therapeutics Announces Changes to its Board of Directors

Retrieved on: 
Monday, April 1, 2024
Cubist Pharmaceuticals, DBV Technologies, MB, Alnylam Pharmaceuticals, Harvard Medical School, University of Cambridge, Faculty, Imperial College London, Development, GSK plc, Biologics license application, Hematology, Patient, ALL, Merck, Bristol Myers Squibb, Marketing, Biogen, Doctor of Philosophy, Bates College, Oxford Biomedica, Sarepta Therapeutics, Pharmaceutical medicine, Therapy, Swedish Orphan Biovitrum, Royal college, FDA, BLA, Autoimmunity, Economics, Food, Pharmaceutical industry

John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.

Key Points: 
  • John H. Johnson advised the Board of his decision to step down from his role as Chairman of the Board and Non-Executive Director.
  • We wish John much success with his new projects,” said Dr. Christian Itin, Chief Executive Officer of Autolus.
  • He is currently a director of Alnylam Pharmaceuticals and chair of Dunad Therapeutics and Gulf of Maine Research Institute.
  • Mr. Bonney has served as a director with many companies previously including Celgene, Kaleido Biosciences, Magenta Therapeutics, Bristol Myers Squibb, Sarepta Therapeutics and Syros Pharmaceuticals.

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
University, Sanofi, Therapeutic index, Growth, GSK plc, Rotman School of Management, Merck Serono, Immunotherapy, Partnership, Patient, SAN, Ipsen, Merck, Cancer, Faculty, Society, TU Dresden, Therapy, Institute of technology, SITC, University of Florida

SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today announced the appointment of Zhen Su, M.D., M.B.A., an experienced physician executive and leader in the development of oncology therapeutics, to the company’s board of directors.
  • “We are excited to welcome Zhen to our board,” said Sean McCarthy, D.Phil., chief executive officer and chairman of CytomX.
  • Dr. Su is currently chief executive officer of Marengo Therapeutics and a member of its Board of Directors.
  • Dr. Su also serves on the board of directors of Karyopharm Therapeutics and as the funding chairperson for the biotech committee of the Society for Immunotherapy of Cancer (SITC).

American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease

Retrieved on: 
Friday, March 15, 2024
American Kidney Fund, Candid (organization), Disease, Caregiver, Vertex Pharmaceuticals, Risk, GSK, Boehringer Ingelheim, GSK plc, Kidney disease, AKF, Therapy, Kidney, Eli Lilly and Company, Platinum, Charity Navigator, Corporation, Pharmaceutical industry

ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .

Key Points: 
  • ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .
  • Corporate Members provide essential support to AKF as it continues its fight against kidney disease on all fronts—from prevention through post-transplant living.
  • “Our Corporate Members—both new and returning—help make the work AKF does for the kidney community possible,” said LaVarne A. Burton, AKF President and CEO.
  • Corporate Members fund AKF’s essential work, including:
    Award-winning, evidence-based kidney health education resources that reach millions of people living with kidney disease, caregivers, living organ donors and health care providers each year
    The Corporate Membership Program is open to institutional partners that support AKF’s mission of fighting kidney disease and helping people live healthier lives.

3Daughters Announces Three New Appointments to Board of Directors

Retrieved on: 
Wednesday, March 13, 2024
Quotient, Thakeham, Alnylam Pharmaceuticals, CDMO, Birth, Labs, GSK plc, Pharmacy, University, Novartis, Dana–Farber Cancer Institute, IUD, University College London, Embryology, IND, MBA, Woman, Doctor of Philosophy, Intrauterine device, Therapy, Drug development, Allergan, Amersham plc, Takeda Oncology, Chief Justice of Hungary, Pharmacia, Birth control

Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.

Key Points: 
  • Miles, Ph.D., and Sarah J. Stevens, Ph.D., to serve on the Company’s Board of Directors.
  • An IND for 3D-001 will be filed this year followed by a Phase 1 clinical trial.
  • Mary Beth Cicero, CEO of 3Daughters, expressed her enthusiasm about the new additions to the board: "We are incredibly excited to have the collective strengths of Michele, Sarah, and Vin on our Board of Directors.
  • With this first product, 3Daughters expects to disrupt the IUD market and establish a position as a major innovator in women's healthcare.

Improving Contract Literacy: Praktio Launches On-demand Course for Marmon's Business Professionals

Retrieved on: 
Tuesday, April 2, 2024
Legal, Technology, Human Resources, Professional Services, Business, Software, Internet, Other Education, Training, Education, HR, Confusion, Exercise, GSK plc, Walking, Partnership, General counsel, Knowledge, Human, Industrial, Multimedia, Family, Berkshire Hathaway, Feedback, Marmon Group

In a fast-paced business environment, understanding and managing contracts is a critical skill for business professionals across all roles and industries.

Key Points: 
  • In a fast-paced business environment, understanding and managing contracts is a critical skill for business professionals across all roles and industries.
  • Praktio's latest on-demand course, Commercial Contracts Essentials , empowers professionals with the acumen to confidently navigate commercial contracts.
  • Our business units see the value in the training, and they like the option to take it at their own pace.
  • "We are excited to release this new course aimed specifically at business professionals who work with contracts."

University of Phoenix College of Doctoral Studies Publishes White Paper on Workforce Trend of Career Betrayal

Retrieved on: 
Saturday, March 23, 2024
Professional Services, Continuing, University, Human Resources, Education, College, Leadership studies, Faculty, Human resource management, Specialization, GSK plc, Nova Southeastern University, Betrayal, Business administration, Research, Information technology, News, Management, Hope, Delta Sigma Pi, University of Phoenix, Phoenix College, Organization, MBA, Marketing, Publication, Capella University, Human resources, Doctor, Disappointment, Northcentral University, Administration, Teaching

University of Phoenix College of Doctoral Studies has published a new white paper by faculty Pamela Ann Gordon, Ph.D., and Julie A. Overbey, Ph.D., titled, “Betrayal: When Job or Career Leads to Disappointment,” exploring a current trend of worker discontent termed “The Great Betrayal” in some media narratives .

Key Points: 
  • University of Phoenix College of Doctoral Studies has published a new white paper by faculty Pamela Ann Gordon, Ph.D., and Julie A. Overbey, Ph.D., titled, “Betrayal: When Job or Career Leads to Disappointment,” exploring a current trend of worker discontent termed “The Great Betrayal” in some media narratives .
  • “Employees invest time, talent, and drive in their job and expect support and fair treatment in return,” shares Overbey.
  • “Acknowledging the betrayal and seeking ways to leverage the experience can add to the resilience and skillset of an individual.”
    Gordon is a staff doctoral instructor at University of Phoenix in the College of Doctoral Studies with almost 21 years of online teaching experience.
  • Overbey is an instructor at University of Phoenix, primarily working with doctoral students as a dissertation chair and teaching courses in leadership and management.

Cerebras Selects Qualcomm to Deliver Unprecedented Performance in AI Inference

Retrieved on: 
Wednesday, March 13, 2024
Semiconductor, Technology, Software, Networks, Artificial Intelligence, Internet, Hardware, Cloud, GSK plc, MX6, Pharmacy, Research, Artificial intelligence, AI, Ultra, NAS, System, LLM, Architecture, FP16, ROI, Cloud computing, Customer service

“These joint efforts are aimed at ushering in a new era of high-performance low-cost inference and the timing couldn’t be better. Our customers are focused on training the highest quality state-of-the-art models that won’t break the bank at time of inference,” said Andrew Feldman, CEO and co-founder of Cerebras. “Utilizing the AI 100 Ultra from Qualcomm Technologies, we can radically reduce the cost of inference – without sacrificing model quality -- leading to the most efficient deployments available today.”

Key Points: 
  • “Utilizing the AI 100 Ultra from Qualcomm Technologies, we can radically reduce the cost of inference – without sacrificing model quality -- leading to the most efficient deployments available today.”
    Leveraging the latest cutting-edge ML techniques and world-class AI expertise, Cerebras will work with Qualcomm Technologies’ AI 100 Ultra to speed up AI inference.
  • NAS service from Cerebras: Using Network Architecture Search for targeted use cases the Cerebras platform can deliver models that are optimized for the Qualcomm AI architecture leading to up to 2x higher inference performance.
  • For more information on the Qualcomm Technologies and Cerebras AI training and inference solutions, please visit the Cerebras blog .
  • The Cerebras CS-3 for AI training and Qualcomm AI 100 Ultra for inference at scale will be available in Q2/Q3 2024.

Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Metabolism, GSK plc, Pharmacy, GSK, Cornell University, Patient, Acquisition, Marker, University, Biology, MBA, Agilent Technologies, Research and development, Therapy, Takeda, Patient safety, TYK2, Vaccine, Human, Pharmaceutical industry

Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.

Key Points: 
  • Nimbus Therapeutics , LLC (“Nimbus Therapeutics” or “Nimbus”), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company’s Board of Directors.
  • “We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple therapeutic areas including oncology, immunology, and metabolism.
  • Dr. Knobil is currently a member of the Board of Directors at Marker Therapeutics (NASDAQ: MRKR) and Pliant Therapeutics (NASDAQ: PLRX).
  • “Nimbus has built a robust R&D organization that has demonstrated continued success in advancing promising discovery-stage science to product development.

Alexion Canada Appoints Karen Heim as New General Manager

Retrieved on: 
Tuesday, April 2, 2024
Circulatory system, Neurology, AstraZeneca, GSK plc, Metabolism, Hematology, Cardiology, Patient, DSM-IV codes, Research, Alexion Pharmaceuticals, Bachelor of Science, Acquisition, University, Senior, Metallurgy, Nephrology, Queen's University, Rare disease, Immunity (medical), Alexion, Ophthalmology, Pharmaceutical industry

MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.

Key Points: 
  • MISSISSAUGA, ON, April 2, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is pleased to announce the appointment of Karen Heim as Vice President and General Manager, Canada, effective April 1st, 2024.
  • In this role, Ms. Heim will lead the Canadian affiliate in its unwavering commitment to helping people affected by rare diseases live longer, healthier lives.
  • "Karen's deep healthcare experience and incredible passion make her the perfect fit to lead this mission in Canada and drive it with expertise and ambition."
  • "Taking on this leadership role at Alexion Canada as it continues to grow, with a focus on research and innovation, is incredibly exciting," says Ms. Heim.